Ophthotech announces first patient enrolled in phase 2b clinical trial of Zimuraź
Ophthotech announced the first patient has been enrolled in the Phase 2b randomized, double-masked, sham-controlled clinical trial assessing the efficacy and safety of Zimuraź (avacincaptad pegol), complement C5 inhibitor, in patients with autosomal recessive Stargardt disease. January 16, 2018